GURU.Markets stock price, segment price, and overall market index valuation
The company's share price QNCX
Quince Therapeutics is a biotech company focused on treating rare diseases. Its stock price reflects its strategy of acquiring and developing promising assets. This chart tells a story, driven by deal news and clinical data.
Share prices of companies in the market segment - Pharma metabolism
Quince Therapeutics focuses on acquiring and developing promising therapeutic assets for the treatment of rare diseases. We classify it in the Pharmaceuticals (Metabolism) sector. The chart below shows how investors view the prospects of this business model.
Broad Market Index - GURU.Markets
Quince Therapeutics is a pharmaceutical company specializing in developing drugs to treat rare diseases. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the outlook for this industry.
Change in the price of a company, segment, and market as a whole per day
QNCX - Daily change in the company's share price QNCX
Quince Therapeutics' daily price change reflects the high volatility inherent in biotech companies that have shifted focus. This metric measures sensitivity to news about the development of a new asset portfolio and is a key element in assessing risk.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Quince Therapeutics' daily price change reflects the high volatility inherent in biotech companies that have shifted focus. This metric measures sensitivity to news about the development of a new asset portfolio and is a key element in assessing risk.
Daily change in the price of a broad market stock, index - GURU.Markets
Quince Therapeutics is a biotech company focused on developing drugs to treat rare metabolic diseases. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization QNCX
For Quince Therapeutics, its year-over-year performance is a story of its strategic pivot. Its 12-month market cap reflects its decision to acquire a biotech company with a promising drug for a rare bone disease, a new bet on the future after the failure of its previous developments.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company focused on treating rare diseases. Its success depends on the commercialization of its approved drugs and the results of its R&D. The chart shows how its focus on orphan diseases and the competitive environment influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Quince Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization QNCX
Quince Therapeutics is a biopharmaceutical company focused on rare diseases. Its monthly performance is driven by progress in its clinical programs. Trial results, as well as M&A activity such as acquisitions, are key drivers.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Quince Therapeutics, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for rare diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its strategy for identifying and developing promising assets is performing in a highly competitive environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Quince Therapeutics is a biopharmaceutical company whose future depends on the results of clinical trials. Its shares don't move in sync with the market, but rather jump around after important news. The chart clearly demonstrates that monthly fluctuations are a reaction to internal events, not to overall investor sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization QNCX
Quince Therapeutics, a biopharmaceutical company focused on rare diseases, exhibits high volatility. Weekly stock performance hinges on news about clinical trials and regulatory decisions, each of which is crucial for the small company.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Quince Therapeutics is focused on developing drugs to treat rare metabolic diseases. In biotech, it's important to understand how the market evaluates niche strategies. This chart will help compare its performance with the pharmaceutical sector and understand the extent to which investors believe in the commercial potential of its developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Quince Therapeutics is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that QNCX's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
QNCX - Market capitalization of the company QNCX
The Quince Therapeutics chart is a financial history of the biotech's strategic pivot. Its market cap reflects the company's new focus on acquiring and developing drugs for rare diseases. Its performance is a barometer of how investors view this new strategy and the potential of its gastroenterology assets.
QNCX - Share of the company's market capitalization QNCX within the market segment - Pharma metabolism
Quince Therapeutics' market share in the pharmaceutical sector reflects its strategy of acquiring and developing promising drugs for rare diseases. Its market share is based not so much on its own research but on its ability to identify and develop undervalued assets with high potential.
Market capitalization of the market segment - Pharma metabolism
Quince Therapeutics is a biotech company focused on rare diseases. The chart below shows the overall market capitalization of this entire sector. Its dynamics reflect investor hopes that focusing on small patient populations can lead to the development of highly effective drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Quince Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. Its market capitalization reflects the potential of its scientific developments. The chart below shows the economic weight of companies solving orphan diseases.
Book value capitalization of the company, segment and market as a whole
QNCX - Book value capitalization of the company QNCX
Quince Therapeutics' book value is its equity. Following its strategic shift, the chart below shows the financial resources the company is dedicating to acquiring and developing new pharmaceutical assets. This is a story about financial transformation, not production.
QNCX - Share of the company's book capitalization QNCX within the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company focused on rare diseases. It acquires and develops promising drugs. Its physical assets are infrastructure for research and development, not for mass production, which is reflected in the chart.
Market segment balance sheet capitalization - Pharma metabolism
Quince Therapeutics uses a "light" model. The company acquires and develops promising drugs, focusing on clinical trials rather than manufacturing facilities. The graph will show whether this capital efficiency is the new standard for the entire pharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Quince Therapeutics' balance sheet is focused on the development and commercialization of drugs for rare diseases. Its book value reflects its strategy of acquiring and developing promising assets in orphan medicine, targeting small patient populations.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - QNCX
Quince Therapeutics is a biotech company focused on rare diseases. Its book value is primarily cash. Its market capitalization reflects the valuation of its lead drug and development strategy. The chart shows how investors assess the chances of success in the orphan disease niche, where drug prices are high but patient numbers are scarce.
Market to book capitalization ratio in a market segment - Pharma metabolism
Quince Therapeutics is a pharmaceutical company focused on acquiring and developing drugs for rare diseases. Its value is determined by its current portfolio of assets and its ability to find new ones. The chart shows how the market values this business model and the potential of its drugs.
Market to book capitalization ratio for the market as a whole
Quince Therapeutics is a biopharmaceutical company focused on developing drugs for rare diseases. The chart shows how the market values its scientific potential. The company's market capitalization, like many clinical-stage biotechs, is a bet investors make on the success of its research and is not tied to its tangible assets.
Debts of the company, segment and market as a whole
QNCX - Company debts QNCX
Quince Therapeutics is a pharmaceutical company focused on acquiring and developing drugs for rare diseases. Its strategy involves using capital, including debt, to acquire promising assets from other companies. This chart illustrates how the company finances its M&A-based growth model.
Market segment debts - Pharma metabolism
Quince Therapeutics is a pharmaceutical company focused on developing drugs for rare diseases. Their business model involves acquiring and developing promising assets. This chart shows common financial metrics for the pharmaceutical sector, which can be used to assess how the company utilizes its capital to discover and advance orphan drugs through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio QNCX
Quince Therapeutics is a pharmaceutical company focused on developing drugs for rare metabolic diseases. Work in this area requires targeted and significant investment. This chart shows the proportion of its research funding that comes from debt. This helps investors assess the financial risks involved in commercializing its products.
Market segment debt to market segment book capitalization - Pharma metabolism
Developing drugs to treat rare metabolic diseases, a focus of Quince Therapeutics, requires specialized expertise and significant investment. This chart shows how the biotech sector as a whole finances its activities. It allows one to assess how the financial model of a company focused on orphan diseases differs from that of large pharmaceutical companies.
Debt to book value of all companies in the market
Quince Therapeutics focuses on treating rare metabolic diseases. Developing drugs for orphan diseases is a niche but capital-intensive process. The chart provides context, allowing one to compare their debt load, necessary for research, with the overall debt level in the pharmaceutical market.
P/E of the company, segment and market as a whole
P/E - QNCX
This metric for Quince Therapeutics, a biopharmaceutical company focused on rare diseases, reflects investor expectations. For a company shifting its strategy and pipeline, the chart shows the market's confidence in its new direction and ability to commercialize its drugs.
P/E of the market segment - Pharma metabolism
This metric represents the average valuation for the biotech sector in which Quince Therapeutics operates. It reflects the overall level of investor optimism regarding rare disease treatments. The chart provides a benchmark for understanding how the market values Quince's development pipeline relative to the broader industry.
P/E of the market as a whole
Quince Therapeutics is a biopharmaceutical company focused on acquiring and developing drugs for rare diseases. Its strategy is to identify promising assets and bring them to market. This chart shows the biotech sentiment. It helps understand how the market views Quince's management's ability to select and manage successful projects, which is key to its business model.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company QNCX
Quince Therapeutics is a biopharmaceutical company focused on treating rare metabolic diseases. Its strategy includes acquiring and developing promising assets. The company's future depends on the success of its lead drug and its ability to secure favorable deals. This chart reflects market expectations regarding its business model and the potential of its developments.
%20P%2FE%20QNCX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-QNCX&v=1772660952785 "Chart of the company's future (projected) P/E QNCX")
Future (projected) P/E of the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company that, after a series of setbacks, has shifted its strategy and is now focusing on acquiring and developing promising assets from other companies. This chart reflects expectations for the biotech sector, providing context for assessing how the market views this "restart" model and the new team's ability to select winners.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772660952795 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Quince Therapeutics is a biopharmaceutical company focused on developing drugs for rare diseases. Their business model involves acquiring and developing promising assets. This graph of general expectations shows how willing investors are to invest in biotech. Market optimism facilitates raising capital for the acquisition of new molecules and clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772660952870 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit QNCX
Quince Therapeutics is a biopharmaceutical company focused on acquiring and developing drugs for rare diseases. This chart shows the financial results of its strategy. Profits will depend on the successful commercialization of its core product and its ability to identify and license new promising assets.
Profit of companies in the market segment - Pharma metabolism
Pluri Inc., formerly Pluristem, is a biotech company developing cell therapies. It is also expanding into other areas, such as agritech. This chart illustrates how companies with a strong scientific platform can seek to diversify its applications, but each new product requires significant investment, and profitability remains a long-term goal.
Overall market profit
Quince Therapeutics is focused on developing and commercializing drugs for rare diseases. Its business model involves acquiring promising assets and bringing them to market. The company's success depends on the careful selection of targets and effectiveness in clinical development, rather than on general economic trends.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company QNCX
Quince Therapeutics is a biotechnology company focused on acquiring and developing drugs for rare diseases. Its profit forecast depends on the success of its selected assets for development. This chart shows analyst expectations regarding its business strategy and the potential of its acquired drugs.
%20profit%20of%20the%20company%20QNCX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-QNCX&v=1772660952922 "Graph of future (projected) profit of the company QNCX")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company that acquires and develops drugs for rare diseases. Its business model is based on identifying promising but undervalued assets. This chart shows profitability forecasts for the pharmaceutical sector. It allows us to assess the success of Quince's strategy to create value in the orphan disease niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772660952956 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Quince Therapeutics is focused on treating rare metabolic diseases. Demand for its potential drugs will be driven by medical needs, not the economy. However, overall profit projections, as shown in this chart, shape the investment climate, affecting the company's ability to raise funds for costly clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772660952983 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - QNCX
Quince Therapeutics is a biopharmaceutical company focused on developing treatments for rare metabolic diseases. Being in the clinical stage, it has no commercial revenue. The valuation on this chart is based on investors' belief in the potential of its developments to address significant unmet needs for patients with rare diseases.
P/S market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company that acquires and develops promising late-stage drugs for the treatment of rare diseases. Its business model is focused on accelerating drug delivery to market. This chart shows the average valuation in the sector, providing insight into how the market views Quince's strategy and portfolio.
P/S of the market as a whole
Quince Therapeutics, formerly Cortexyme, has refocused its operations on acquiring and developing drugs for rare diseases. Its business model is based on identifying promising assets. This chart shows the average investor-to-revenue ratio, which allows one to assess the value of a company operating under an opportunistic pharmaceutical model.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company QNCX
Quince Therapeutics is a biopharmaceutical company focused on acquiring and developing drugs for rare diseases. This chart shows how investors assess the future success of its strategy. This assessment is based on the potential revenue from the drugs the company successfully brings to market after acquiring and developing them.
%20P%2FS%20QNCX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-QNCX&v=1772660953125 "The graph of the company's future (projected) P/S QNCX")
Future (projected) P/S of the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company focused on developing treatments for rare metabolic diseases. Its strategy is to acquire and develop promising assets. The chart shows how investors estimate Quince's future sales, reflecting the potential of its portfolio and its ability to bring its drugs to market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772660953186 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Investor optimism about future revenues hinges on finding solutions for rare diseases. Quince Therapeutics focuses on developing and commercializing drugs for these conditions. Their strategy demonstrates that even niche markets can be attractive and that medical progress can be achieved, in part, by helping patients with orphan diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772660953240 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales QNCX
Quince Therapeutics is a biopharmaceutical company focused on developing drugs for rare diseases. Its financial curve currently reflects revenue from asset sales and partnerships rather than commercial sales, as the company is undergoing a transformation and identifying its core therapeutic niche.
Sales of companies in the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company focused on acquiring, developing, and commercializing drugs for rare diseases. This chart shows total revenue in the metabolism-focused pharmaceutical segment. It illustrates a business model focused on identifying promising assets to address unmet medical needs.
Overall market sales
Quince Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of rare metabolic diseases. Its business model is based on the acquisition and development of promising assets. Success depends on clinical trial results and regulatory approvals. This overall economic climate impacts the availability of capital to fund such developments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company QNCX
Quince Therapeutics is a biopharmaceutical company focused on acquiring and developing drugs for rare diseases. Its future revenue depends on the success of its chosen strategy and clinical trials. The chart shows speculative analyst forecasts, which are a bet on the company's ability to identify and develop promising assets.
%20sales%20of%20the%20company%20QNCX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-QNCX&v=1772660953387 "Schedule of future (projected) sales of the company QNCX")
Future (projected) sales of companies in the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company focused on developing drugs for rare diseases. Its strategy includes the acquisition and development of promising assets. This chart displays projected sales for the entire metabolism-related pharmaceutical segment, demonstrating analysts' overall growth expectations for this therapeutic area.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772660953392 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Quince Therapeutics is a biopharmaceutical company focused on acquiring and developing drugs for rare diseases. Its business model depends on successfully selecting assets and advancing them through clinical trials. This overall economic activity schedule impacts capital availability and the valuation of potential acquisitions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772660953425 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality QNCX
Quince Therapeutics is a biotech company focused on rare diseases. This metric reflects its financial strategy following its business transformation. It shows how the company manages its resources and converts any revenue (such as from asset sales) into the results needed to fund its new mission.
Market segment marginality - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company focused on developing treatments for rare metabolic diseases. Being in the clinical stage, its financial metrics reflect its investment in R&D. This chart provides insight into the company's operating model and cost structure compared to other companies in its niche.
Market marginality as a whole
Quince Therapeutics (formerly Cortexyme) is a biopharmaceutical company focused on developing drugs to treat rare diseases. After failing to develop Alzheimer's disease, the company shifted its strategy. Their future depends on the success of their new portfolio. This overall profitability curve doesn't directly impact them, but it is important for raising new capital.
Employees in the company, segment and market as a whole
Number of employees in the company QNCX
Quince Therapeutics is a biopharmaceutical company focused on treating rare diseases. Its strategy emphasizes a small but highly effective team. This chart shows the dynamics of a compact team of scientists and managers working to acquire and develop promising therapeutic assets.
Share of the company's employees QNCX within the market segment - Pharma metabolism
Quince Therapeutics is focused on developing drugs to treat rare diseases. This chart shows the percentage of clinicians and researchers in the orphan disease field that the company attracts. Its small but highly specialized team is working to create solutions for patients with very rare diagnoses.
Number of employees in the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company focused on acquiring and developing drugs for rare diseases. This chart shows the overall employment in the metabolic research sector. It illustrates the company's business model, which involves identifying promising but undervalued pharmaceutical assets and bringing them to market.
Number of employees in the market as a whole
Quince Therapeutics is a biopharmaceutical company focused on acquiring, developing, and commercializing drugs for rare diseases. Its business model is aimed at addressing unmet medical needs. This total employment chart also reflects the contribution of companies like these, which, despite operating in narrow niches, create highly skilled jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company QNCX (QNCX)
Quince Therapeutics is a biopharmaceutical company developing drugs to treat rare diseases. This chart is a classic example of biotech. The very high market capitalization per employee means the market is not evaluating current operations, but the enormous potential of the drug being developed by a small but highly qualified team.
%20of%20the%20company%20QNCX%20(QNCX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-QNCX-QNCX&v=1772660953651 "Chart of market capitalization per employee (in thousands of dollars) of the company QNCX (QNCX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Quince Therapeutics is a pharmaceutical company focused on developing drugs for rare metabolic diseases. Their valuation is determined by the potential of their lead or sole candidate. This metric demonstrates the enormous value the market places on the success of this drug. A high valuation reflects investor hopes for a breakthrough in the treatment of rare diseases.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772660953686 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Quince Therapeutics is a biopharmaceutical company focused on rare diseases. Its strategy may include the acquisition and development of promising assets. The employee's valuation will reflect not only internal developments but also the value of the acquired drug portfolio, as well as the management team's ability to identify and develop such opportunities.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772660953690 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company QNCX (QNCX)
Quince Therapeutics is a biotech company focused on rare diseases. Their model is to acquire and develop promising R&D assets. This chart reflects this strategy, showing the net loss (R&D and asset acquisition costs) per the small staff managing this portfolio.
%20Chart%20QNCX%20(QNCX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-QNCX-QNCX&v=1772660953716 "Company Profit Per Employee (in thousands of dollars) Chart QNCX (QNCX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Quince Therapeutics focuses on drugs for rare diseases. In this niche, this metric can be very high. The chart shows the industry average. QNCX's success depends on its ability to commercialize high-priced drugs for small patient populations, allowing a small team to generate significant revenue.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772660953759 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Quince Therapeutics (QNCX) is a biopharmaceutical company focused on developing treatments for rare metabolic diseases. Their business is focused on R&D in a narrow niche. This chart shows that the company is in the clinical stage. Earnings per employee are negative, as all resources are invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772660953765 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee QNCX (QNCX)
For Quince Therapeutics, a company focused on treating rare diseases, this chart reflects its commercial strategy. Revenue per employee growth will depend on the successful acquisition and commercialization of drugs in niche markets with unmet medical needs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-QNCX-QNCX&v=1772660953794 "Sales chart per company employee QNCX (QNCX)")
Sales per employee in the market segment - Pharma metabolism
Quince Therapeutics is a biopharmaceutical company focused on developing drugs to treat rare metabolic diseases. This is R&D. This metric reflects the average revenue per employee in the segment. It allows one to assess how productive their scientific team is in their niche compared to other biotech companies working with orphan diseases.
Sales per employee for the market as a whole
Quince Therapeutics (QNCX) is a biopharmaceutical company focused on acquiring and developing drugs for rare diseases. This metric reflects their strategy. While they are still seeking assets or are in the early stages of R&D, it may be low. An increase in this metric will indicate the success of the acquired drug and the start of its commercialization.
Short shares by company, segment and market as a whole
Shares shorted by company QNCX (QNCX)
Quince Therapeutics is a biotech company that acquired its core asset but lacks a long history of developing it. The company focuses on rare diseases. This chart reflects investor skepticism about its ability to successfully conduct clinical trials and commercialize a drug acquired through a complex acquisition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-QNCX-QNCX&v=1772660953927 "Short Shares Chart for the Company QNCX (QNCX)")
Shares shorted by market segment - Pharma metabolism
Quince Therapeutics (QNCX) is a biopharmaceutical company whose strategy is to acquire and develop neglected or low-priority drugs for rare diseases. This chart shows the overall short position in the rare disease biotech sector. It reflects market skepticism about their business model or the potential of their acquired assets.
Shares shorted by the overall market
Quince Therapeutics is a clinical-stage biotech. Its value reflects its hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring constant refinancing for R&D, and QNCX is caught in the middle of this sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator QNCX (QNCX)
This oscillator for Quince Therapeutics reflects binary bets in biotech. The company is focused on rare diseases. In this sector, news is king. Positive clinical trial data or regulatory approvals spark euphoria among investors, pushing the indicator into overbought territory (above 70). Any hint of failure or delay leads to panic selling (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-QNCX-QNCX&v=1772660954080 "RSI 14 indicator chart for the company's stock QNCX (QNCX)")
RSI 14 Market Segment - Pharma metabolism
Quince (QNCX) is a biotech company focused on rare metabolic diseases. The "Pharma Metabolism" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is QNCX's growth due to its R&D or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
For Quince Therapeutics, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast QNCX (QNCX)
Quince Therapeutics is a biopharmaceutical company focused on treating rare metabolic diseases. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their assessment of the company's R&D portfolio and the likelihood of its drugs being approved.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-QNCX-QNCX&v=1772660954170 "A chart showing analyst consensus forecasts for the expected stock price. QNCX (QNCX)")
The difference between the consensus estimate and the actual stock price QNCX (QNCX)
QNCX - Quince Therapeutics is a biotech company focused on developing drugs to treat rare metabolic diseases. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the company's scientific platform and R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-QNCX-QNCX&v=1772660954174 "A chart showing the difference between the consensus forecast and the actual stock price. QNCX (QNCX)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Quince Therapeutics (QNCX) is a biopharmaceutical company focused on developing drugs for rare metabolic diseases. This chart shows analysts' overall expectations for the metabolic sector. It reflects whether experts believe in the success of rare disease R&D or consider the sector too risky.
Analysts' consensus forecast for the overall market share price
Quince Therapeutics is a biotech company that (after a series of setbacks) has transformed itself and now focuses on acquiring and developing drugs for rare diseases. This chart shows the overall risk appetite. For Quince, a company in a state of "reset," overall market optimism is critical to raising the capital needed to fund its new strategy.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index QNCX
Quince (QNCX) is a biotech that has rebounded after a setback. Their only assets now are EryDel, a red blood cell platform, and their massive cash balance. This chart is the company's wallet. Its valuation is essentially the value of their cash (minus expenses) and the option that their new technology (drug delivery via red blood cells) will be successful.
AKIMA Market Segment Index - Pharma metabolism
Quince Therapeutics is a pharmaceutical company focused on developing drugs to treat rare metabolic diseases. This chart shows the average pharma sector index. It allows investors to assess how Quince, with its narrow focus on orphan diseases, compares to the average pharmaceutical company based on a combination of factors.
The AKIM Index for the overall market
Quince Therapeutics is a biotech company using its Bone Targeting System delivery platform to treat rare bone diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which focuses on acquisitions and asset development, compares to overall economic trends.
